Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer

BACKGROUND: Immunotherapy has revolutionized therapeutic patterns of small cell lung cancer (SCLC). Human leukocyte antigen class II (HLA class II) is related to antitumor immunity. However, the implications of HLA class II in SCLC remain incompletely understood. MATERIALS AND METHODS: We investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Peixin, Zhao, Lishu, Wang, Hao, Zhang, Liping, Zhang, Wei, Zhu, Jun, Yu, Jia, Zhao, Sha, Li, Wei, Sun, Chenglong, Wu, Chunyan, He, Yayi, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351500/
https://www.ncbi.nlm.nih.gov/pubmed/34362829
http://dx.doi.org/10.1136/jitc-2021-002554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351500/
https://www.ncbi.nlm.nih.gov/pubmed/34362829
http://dx.doi.org/10.1136/jitc-2021-002554

Ejemplares similares